Iberdomide Triplet Extends Progression Free Survival in Myeloma

Company Bristol Myers Squibb Event Type Phase 3 confirmatory result (source-gap catch-up of 8 October announcement) Modality Oral cereblon E3-ligase modulator combination (iberdomide + daratumumab + dexamethasone) Asset Iberdomide (ZDd regimen) Target Cereblon; IKZF1/IKZF3 degradation Disease Area Relapsed or refractory multiple myeloma Summary Bristol Myers…